Navigation Links
Variation in make-up of generic epilepsy drugs can lead to dosing problems
Date:6/30/2011

Generic anti-epilepsy drugs, pharmaceutical products similar to brand-name versions, save consumers billions of dollars each year, but some are different enough from branded formulations that they may not be effective, particularly if patients switch between two generic drugs, a new study by Johns Hopkins researchers suggests.

A report on the study, published online and in an upcoming issue of Annals of Neurology, raises questions about whether some generic products are safe and effective when a narrow dose range separates patients from help and harm.

"In most areas of medicine, generics work well and are an incredible savings for health plans and patients," explains study leader Gregory Krauss, M.D., professor of neurology at the Johns Hopkins University School of Medicine. However, he adds, epilepsy patients whose condition is well-controlled on brand-name medications often worry that switching to generic versions might change blood medication levels, leading to seizures and side effects. These fears aren't without merit; studies have shown that patients frequently complain of breakthrough seizures when switched to generic drugs.

Consequently, Krauss and his colleagues decided to compare how generics stack up to their brand-name counterparts, as well as other generic formulations for the same drug, using the bioequivalence study data that generic manufacturers generate to gain U.S. Food and Drug Administration (FDA) approval. Such data, held privately by the FDA, are mandated by the Drug Price Competition and Patent Term Restoration Act (informally known as the Hatch-Waxman Act). Part of this law, passed during the Reagan administration, states that generic formulations must have a peak blood concentration and total amount absorbed that falls between 80 percent and 125 percent of the name-brand version.

That range is suitable for the vast majority of pharmaceuticals, says Krauss. However, he notes, for some "critical dose" drugs that have a high potential for over- or underdosing, the window could be significantly narrower.

After securing bioequivalency data for 141 generic epilepsy drugs from the FDA using Freedom of Information Act requests, Krauss and his colleagues found that peak blood concentration and total amount absorbed differed by less than 15 percent between the vast majority of generics and their brand-name equivalents. However, some manufacturers had generic products that were at the upper or lower edge of the acceptance limits, and these drugs varied markedly between each other compared to the brand-name drugs-as much as 30 percent between generic formulations for one drug in particular, oxycarbazepine.

Since each brand-name drug can have many different generic counterparts - and pharmacies frequently switch between different generic versions - prescriptions for some generic drugs could prove unsafe for epilepsy patients, Krauss notes.

"Overall, generics should be used for treating epilepsy," Krauss says. "However, we suggest that patients and pharmacies should be cautious when switching between different generic version of anticonvulsants, and policy makers should evaluate whether standards that set the range for generics' similarity to brand name versions are appropriate for every drug. For patients with epilepsy, that may not be the case."

He notes that for other pharmaceuticals in which over- or underdosing by narrow margins may also be a problem, such as chemotherapeutics for cancer, the same questions can be raised.


'/>"/>

Contact: Christen Brownlee
cbrownlee@jhmi.edu
410-955-7832
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Gene Variation May Explain Some Female Infertility Cases
2. Gene variation linked to infertility in women, study finds
3. MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men
4. Genetic variation linked to longer telomeres and lower risk of bladder cancer
5. Genetic variation cuts bladder cancer risk, protects chromosome tips
6. ICUROS study finds international variations in quality of life loss after fracture
7. Gene Variation Linked to Altruism
8. Regional variation in health-care spending and utilization higher in Medicare than private sector
9. Chromosomal variations found in early passage female embryonic stem cells
10. Three Genes Linked to Variations in Eye Color
11. 9-country study shows wide variations in how women with early breast cancer are treated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with gluten intolerance ... you may be interested in participating in a research study that focuses on family ... understand more about the relational aspects of adults who have gluten sensitivities who cohabitate ...
(Date:8/19/2017)... (PRWEB) , ... August 18, 2017 , ... ... Drug Administration Reauthorization Act of 2017, legislation that provides for greater public access ... to moderate hearing loss to access OTC hearing aids without being seen by ...
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the United States ... two sides. There are not two sides to hatred, bigotry, discrimination, and a white ... and the NPEIV stands against all forms of such hatred and discrimination in this ...
(Date:8/18/2017)... , ... August 19, 2017 , ... ... Authority of Thailand presided over the Amazing Thailand Health and Wellness Tourism Showcase ... , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and Business at TAT ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... campaign, advocating for active, healthy lifestyles and highlighting the importance of proactive eye ... hearing impairments and shares the latest innovations in hearing aid technology. , ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017 AccuGenomics, Inc., a diagnostic ... today announced that the company has provided an AccuKit ... North Carolina at Chapel Hill and to Qura Therapeutics ... characterize and quantify HIV reservoir and viral expression in ... The HIV Cure Center is a joint initiative between ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel , Aug. ... a leading developer of adult stem cell technologies for ... ending June 30, 2017. ... for our pivotal Phase 3 trial to investigate NurOwn ... President and Chief Executive Officer of BrainStorm. "We have ...
(Date:8/10/2017)... -- Physical Rehabilitation Network (PRN), acquired the long-standing outpatient rehabilitation clinic, ... . The reputable clinic will continue to be co-owned and ... staff of four clinicians. Lipkin received his doctorate in physical ... years of experience with a strong background in manual therapy. ... 10th PRN clinic in and around the Denver ...
Breaking Medicine Technology: